Evidence map›Paper›PMID 23084793›Full record

ReviewCurrent opinion in pharmacology2013

Immune regulation toward immunomodulation for neuroprotection in glaucoma.

Gülgün Tezel

Abstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Protective Effects of Lipoxin AbioRxiv : the preprint server for biology · 2024
    Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gülgün TezelDepartments of Ophthalmology & Visual Sciences and Anatomical Sciences & Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA. gulgun.tezel@louisville.edu
University of Louisville · US

Funding

TNF-alpha in Cell Death & Neuroprotection in GlaucomaR01EY013813 · NEI · UNIVERSITY OF LOUISVILLE · PI TEZEL, GULGUN · 2003 to 2011
$2.7M
Proteomic Analysis of Retinal Ganglion Cell Death in GlaucomaR01EY017131 · NEI · UNIVERSITY OF LOUISVILLE · PI TEZEL, GULGUN · 2008 to 2010
$1.1M
NEI NIH HHS R01 EY013813NEI NIH HHS R01 EY017131
6 · The paper itself

Abstract

Although the immune system functions to preserve and restore tissue homeostasis, accumulating risk factors, prolonged glial activation, and sustained release of pro-inflammatory mediators in glaucoma may lead to a failure in the regulation of stress-induced immune response, and innate immune cells, autoreactive T cells, autoantibodies, and excess complement attack may exhibit potent stimuli that harm retinal ganglion cell somas, axons, and synapses. Identification of the cellular and molecular components of immune response pathways can provide immunomodulatory treatment strategies to attenuate neuroinflammation, protect neural tissue from collateral injury, and enhance endogenous recovery processes. This review highlights the current knowledge of molecular mechanisms regulating neuroinflammation in glaucoma.

Indexed as

AnimalsGlaucomaHumansImmunomodulationNeuroglia

Identifiers

PMID23084793
PMCPMC3529855
OpenAlexW2019547548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.